The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under Dual Antiplatelet Medication.
Title: Observational Registry With p64 MW HPC and p48 MW HPC in Unruptured Anterior Circulation Aneurysms Under Dual Antiplatelet Medication. Purpose: To assess safety and effectiveness of p64 MW HPC or p48 MW HPC under Dual Antiplatelet Medication in consecutive patients with unruptured anterior circulation aneurysms. Follow-up intervals: Independent follow-ups (after 3 to 6 months and after 12 months and after 24 months) according to site specific standard.
Study Type
OBSERVATIONAL
Enrollment
90
Endovascular treatment of intracranial aneurysms with flow diversion.
Shastin Central Hospital
Ulaanbaatar, Bayangol District, Mongolia
RECRUITINGSafety endpoint
Occurence of ischemic or hemorrhagic stroke. Incidence of ischemic or hemorrhagic stroke in the territory supplied by the treated artery.
Time frame: Within 30 days after the intervention
Safety endpoint
Occurence of all adverse events and serious adverse events, related directly or indirectly to the intervention, the used device or the required medication.
Time frame: Within the first 12 months after the intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.